JPMorgan Chase & Co. Decreases Stock Position in Fate Therapeutics, Inc. (NASDAQ:FATE)

JPMorgan Chase & Co. decreased its position in Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) by 9.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,669,562 shares of the biopharmaceutical company’s stock after selling 167,742 shares during the quarter. JPMorgan Chase […]